Advertisement

Are there immunohistochemical markers for the differential diagnosis of renal cell neoplasms, especially when tumor cells have an eosinophilic/granular cytoplasm?

Abstract

Standard microscopic examination is sufficient for classifying most renal tumors, but there are occasions on which ancillary studies are helpful in reaching the final diagnosis. They are, in order of practical usefulness: immunohistochemistry, chromosomal analysis by fluorescence in situ hybridization (FISH), and molecular analysis. The last method should be considered for renal cell carcinomas arising in children or young adults.

Keywords

Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Papillary Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Renal Oncocytoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shen SS, Chirala M, Krishnan B, Amato R, Liu YL, Zhai J, Truong LD (2005) Renal cell neoplasm with dual differentiation of proximal and distal nephron: an immunohistochemical study. Mod Pathol 18(suppl 1):164A.Google Scholar
  2. 2.
    Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KS, Badaro R, Reed SG (2000) Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60:1677–1682.PubMedGoogle Scholar
  3. 3.
    Jiang Z, Fanger G, Woda B, Banner BF, Algate P, Dresser K, Xu J, Chu PG (2003) Expression of alphamethylacyl-CoA racemase (P504S) in various malignant neoplasms and normal tissue: a study of 761 cases. Hum Pathol 34:792–796.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhou M, Chinnaiyan AM, Kleer GC, Lucas PC, Rubin MA (2002) Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 26: 926–931.PubMedCrossRefGoogle Scholar
  5. 5.
    Tretiakova MS, Sahoo S, Takahashi M, Turkyilmaz M, Vogelzang NJ, Lin F, Krausz T, The BT, Yang XJ (2004) Expression of alpha-methyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 28: 69–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Quian C-N, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, Furge KA, Kanayama H, Kagawa S (2003) Molecular subclassification of kidney tumors and discovery of new diagnostic markers. Oncogene 22:6810–6818.PubMedCrossRefGoogle Scholar
  7. 7.
    Li C, Jiang J, Banner B, Wu C-L (2005) Expression of alpha-methylacyl-CoA racemase (AMACR)/P504S in renal neoplasms. Mod Pathol 18(suppl 1):152A.Google Scholar
  8. 8.
    Hes O, Brunelli M, Michal M, Cossu Rocca P, Chilosi M, Mina M, Menestrina F, Martigoni G (2005) Oncocytic papillary renal cell carcinoma: a clinicopathologic study of 9 cases. Mod Pathol 18(suppl 1):145A.Google Scholar
  9. 9.
    Chuang ST, Chu P, Sugimura J, Tretiakova M, Papavero V, Wang K, Tan M, Lin F, The BT, Yang XJ (2005) Overexpression of glutathione S-transferase alpha in clear cell renal cell carcinoma. Am J Clin Pathol 123:421–429.PubMedCrossRefGoogle Scholar
  10. 10.
    Tu JJ, Chen Y-T, Hyjek E, Tickoo SK (2005) Carbonic anhydrase IX as a highly sensitive and specific marker of clear cell renal cell carcinoma: a comprehensive immunohistochemical study using a panel of commonly utilized antibodies in the differential diagnosis of renal cell tumors. Mod Pathol 18(suppl 1):169A.Google Scholar
  11. 11.
    McIntosh GG, Lodge AJ, Watson P, Hall AG, Wood K, Anderson JJ, August B, Horne CW, Milton ID (2003) NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol 154:77–82.Google Scholar
  12. 12.
    Avery AK, Beckstead J, Renshaw AA, Corless CL (2000) Use of antibodies to RCC and CD10 of renal neoplasms. Am J Surg Pathol 24:203–210.PubMedCrossRefGoogle Scholar
  13. 13.
    Matrignoni G, Pea M, Brunelli M, Chilosi M, Zamo A, Bertaso M, Cossu-Rocca P, Eble JN, Mikuz G, Puppa G, Badoual C, Ficarra V, Novella G, Bonetti F (2004) CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 17:1455–1463.CrossRefGoogle Scholar
  14. 14.
    Matrignoni G, Pea M, Chilosi M, Brunelli M, Scarpa A, Colato C, Tardanico R, Zamboni G, Bonetti F (2001) Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol 14:760–767.CrossRefGoogle Scholar
  15. 15.
    Young AN, de Oliveira Salles PG, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS, Amin MB (2003) Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarray. Am J Surg Pathol 27:199–205.PubMedCrossRefGoogle Scholar
  16. 16.
    Krystal GW, Hines SJ, Organ CP (1996) Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Caner Res 56: 370–376.Google Scholar
  17. 17.
    Mauduit C, Hamamah S, Behnamed M (1999) Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update 5:535–545.PubMedCrossRefGoogle Scholar
  18. 18.
    Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938–1942.PubMedCrossRefGoogle Scholar
  19. 19.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations in c-kit in human gastrointestinal stromal tumors. Science 279:577–580.PubMedCrossRefGoogle Scholar
  20. 20.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman SL, Capedeville R, Dimitrijevic S, Druker B, Demetri G (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S (2003) Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 22:847–852.PubMedCrossRefGoogle Scholar
  22. 22.
    Petit A, Castillo M, Santos M, Mellado B, Alcover JB, Mallofre C (2004) KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 28:676–678.PubMedGoogle Scholar
  23. 23.
    Pan C-C, Chen PC-H, Chiang H (2004) Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 121: 878–883.PubMedCrossRefGoogle Scholar
  24. 24.
    Huo L, Patton KT, Adley BP, Gupta R, Papavero V, Laskin WB, Yeldandi A, Yang XJ (2004) Analysis of c-kit expression in 171 renal neoplasms. Mod Pathol 17(suppl 1):150A.Google Scholar
  25. 25.
    Taki A, Nakatani Y, Misugi K, Yao M (1999) Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases. Mod Pathol 12:310–317.PubMedGoogle Scholar
  26. 26.
    Storkel S, Eble JN, Adlakha K, Amin MB, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K (1997) Classification of renal cell carcinoma: workshop no. 1—Union Internationale Contre le Cancer (UICC) and American Joint Committee on Cancer (AJCC). Cancer 80:987–989.PubMedCrossRefGoogle Scholar
  27. 27.
    Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO (1994) Evidence for a role of the epithelial glycoprotein 40 (EP-CAM) in epithelial cellcell adhesion. Cell Adhes Commun 2:417–428.PubMedCrossRefGoogle Scholar
  28. 28.
    Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener P-A, Moch H (2005) Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol 29:83–88.PubMedCrossRefGoogle Scholar
  29. 29.
    Adley BP, Teh BT, Yang XJ (2006) Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Anal Quant Cytol Histol 28:228–236.PubMedGoogle Scholar
  30. 30.
    Magi-Galluzzi C, Levin HS, Willis-Epinger G, Hood L, Zhou M (2005) CK7, CK20, and CD15 can reliably differentiate renal oncocytoma from chromophobe renal cell carcinoma. Mod Pathol 18(suppl 1):154A.Google Scholar
  31. 31.
    Berbescu EA, Lager DJ (2005) E-cadherin pattern of expression differentiates chromophobe renal cell carcinoma from oncocytoma: An immunohistochemical study of 137 renal neoplasms. Mod Pathol 18(suppl 1): 129A.Google Scholar
  32. 32.
    Rocca PC, Brunelli M, Gobbo S, Eccher A, Bragantini E, Mina MM, Ficarra V, Zattoni F, Zamò A, Pea M, Scarpa A, Chilosi M, Menestrina F, Bonetti F, Eble JN, Martignoni G (2007) Diagnostc utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. Mod Pathol 20:722–728.PubMedCrossRefGoogle Scholar
  33. 33.
    Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L (2005) Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol 18:161–169.PubMedCrossRefGoogle Scholar
  34. 34.
    Paraf F, Viellefond A, Bouvier R, Droz D, Toublanc M, Dupuytren CHRU (1999) Collecting duct carcinoma of the kidney: study of 29 cases. Mod Pathol 12(suppl):103A.Google Scholar
  35. 35.
    Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Orsola I (2005) Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology 65:49–54.PubMedCrossRefGoogle Scholar
  36. 36.
    Srigley JR, Moch H (2004) Carcinoma of the collecting ducts of Bellini. In: Eble JN, Sauyer G, Epstein JI, Sesterhenn IA (eds) World Health Organization classification of tumours. IARC Press, Lyon, pp 33–38.Google Scholar
  37. 37.
    Murphy WM, Beckwith JB, Farrow GM (1994) Tumors of the kidney, bladder, and related urinary structures. Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Bethesda, pp 92–145.Google Scholar
  38. 38.
    Genega EM, Hutchinson B, Reuter VE, Gaudin PB (1999) Immunophenotype of intermediate and high grade prostatic and urothelial carcinoma. Mod Pathol 12(suppl 1): 87A.Google Scholar
  39. 39.
    Parker DC, Folpe AL, Bell J, Oliva E, Young RH, Cohen C, Amin MB (2003) Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasiv, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 27:1–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Wu SL, Kathari P, Wheeler TM, Reese T, Connelly JH (2002) Cytokeratins 7 and 20 immunoreactivity in chromophobe renal cell carcinomas and renal oncocytomas. Mod Pathol 15:712–717.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Personalised recommendations